Previous 10 | Next 10 |
Vanda Pharmaceuticals Comments on FDA's Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved Drugs PR Newswire WASHINGTON , Jan. 12, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) submitted a c...
2023-12-14 11:20:18 ET Summary A PDUFA date of September 18th, 2024 has been set by the FDA to review whether or not the tradipitant should be approved for gastroparesis. The global gastroparesis treatment market is projected to reach $7.19 billion by 2029. An sNDA for the rev...
2023-12-07 07:36:32 ET Vanda Pharmaceuticals ( NASDAQ: VNDA ) has acquired the U.S. and Canadian rights to relapsing multiple sclerosis drug Ponvory (ponesimod) from J&J ( NYSE: JNJ ) unit Actelion for $100M. Approved by FDA and Health Canada, Ponvory is indicate...
Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis PR Newswire WASHINGTON , Dec. 7, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nas...
2023-12-05 05:53:10 ET Vanda Pharma ( NASDAQ: VNDA ) shares jumped 19% premarket on Tuesday as the FDA accepted the new drug application (NDA) for tradipitant, an experimental drug for the treatment of gastroparesis. Tradipitant is a neurokinin 1 antagonist licensed by V...
Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis PR Newswire WASHINGTON , Dec. 4, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today an...
2023-11-20 11:49:37 ET Summary Intra-Cellular Therapies, Inc. is a mid-cap biopharmaceutical company focused on developing treatments for neuropsychiatric and neurological disorders. The company's commercial asset, Caplyta, has achieved significant sales growth and is an exciting ...
Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences PR Newswire WASHINGTON , Nov. 9, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA ) today announced that the company will participate in the following upc...
2023-11-08 21:36:04 ET Vanda Pharmaceuticals Inc. (VNDA) Q3 2023 Results Conference Call November 08, 2023 04:30 PM ET Company Participants Kevin Moran - SVP, CFO and Treasurer Dr. Mihael Polymeropoulos - President, CEO and Chairman Tim Williams - General Counsel...
2023-11-08 16:07:14 ET More on Vanda Pharmaceuticals Vanda Pharmaceuticals: Value In The Biotech Space Seeking Alpha’s Quant Rating on Vanda Pharmaceuticals Historical earnings data for Vanda Pharmaceuticals Financial information for Vanda Pharmaceutic...
News, Short Squeeze, Breakout and More Instantly...
Vanda Pharmaceuticals Inc. Company Name:
VNDA Stock Symbol:
NASDAQ Market:
Vanda Pharmaceuticals Inc. Website:
2024-07-17 04:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-11 07:00:07 ET Charles Duncan from Cantor Fitzgerald issued a price target of $11.00 for VNDA on 2024-07-11 06:12:00. The adjusted price target was set to $11.00. At the time of the announcement, VNDA was trading at $5.21. VNDA currently trades -22.96% versus its...
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex PR Newswire WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of ...